Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,118 across all filing types
Latest filing 2023-09-13 Annual Report
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
FY23 Full Year Statutory Accounts 82 pages 3.9MB
Annual Report Classification · 100% confidence The document is a detailed financial report for Mayne Pharma Group Limited for the year ended 30 June 2023. It includes comprehensive financial statements such as the Consolidated Statement of Profit or Loss, Statement of Financial Position, Cash Flows, and Notes to the Financial Statements. It also contains the Directors' Report, Remuneration Report, Auditor's Independence Declaration, and Independent Auditor's Report. The presence of these detailed financial statements and reports, along with the fiscal year-end date, clearly identifies this as an Annual Report. The document is lengthy (15,000 characters) and contains substantive financial data and analysis, not just an announcement or summary. Therefore, the correct classification is Annual Report (10-K). FY 2023
2023-09-13 English
FY23 Full Year Statutory Accounts 82 pages 4.1MB
Annual Report Classification · 100% confidence The document is a detailed financial report for Mayne Pharma Group Limited for the year ended 30 June 2023. It includes comprehensive financial statements such as the Directors' Report, Remuneration Report, Auditor's Independence Declaration, Consolidated Statement of Profit or Loss and Other Comprehensive Income, Consolidated Statement of Financial Position, Cash Flows, Changes in Equity, Notes to the Financial Statements, Directors' Declaration, and Independent Auditor's Report. The document also contains detailed financial data, restatements, and commentary on operations and developments during the year. The presence of full financial statements and the annual period covered (year ended 30 June 2023) clearly identifies this as an Annual Report. The document is lengthy (15,000 characters) and contains substantive financial data, not merely an announcement or certification. Therefore, the correct classification is Annual Report (10-K). FY 2023
2023-09-13 English
Update - Notification of buy-back - MYX 6 pages 27.7KB
Transaction in Own Shares Classification · 100% confidence The document is a detailed notification of a daily buy-back of shares by Mayne Pharma Group Limited. It includes specifics such as the number of securities bought back, prices paid, broker details, dates, and regulatory compliance references (e.g., ASX listing rules). The content focuses exclusively on the company's share repurchase activity and does not contain financial statements, earnings data, or management commentary. It is not an announcement of a report publication but a substantive update on share buy-back transactions. Therefore, the document fits the category of 'Transaction in Own Shares' (POS).
2023-09-12 English
Update - Notification of buy-back - MYX 6 pages 27.7KB
Transaction in Own Shares Classification · 100% confidence The document is a detailed notification of a buy-back program by Mayne Pharma Group Limited, including daily updates on the number of securities bought back, prices paid, broker information, and regulatory compliance details. It specifically mentions 'Daily buy-back notification' multiple times and provides transactional data related to the company's repurchase of its own shares. This matches the description of 'Transaction in Own Shares' filings, which report on the company's buying back or selling its own shares. The document is not an announcement of a report, nor is it a financial report or management discussion. Therefore, the correct classification is POS (Transaction in Own Shares).
2023-09-11 English
Update - Notification of buy-back - MYX 6 pages 27.7KB
Transaction in Own Shares Classification · 100% confidence The document is a detailed notification of a buy-back program by Mayne Pharma Group Limited. It includes specifics such as the type of buy-back (on-market), dates, number of securities bought back, prices paid, broker information, and regulatory compliance details. The content is focused on the company's repurchase of its own shares rather than financial results, management changes, or other report types. This matches the definition of a Transaction in Own Shares (POS) filing, which reports on share repurchase activities. The document length and detail confirm it is the actual notification, not just an announcement of a report publication or a brief summary.
2023-09-10 English
Mayne Pharma presentation at HC Wainwright Conference in NY 24 pages 1.1MB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 11 September 2023 from Mayne Pharma Group Limited regarding a presentation at the H.C. Wainwright 25th Annual Global Investment Conference. It includes detailed presentation slides content such as FY23 performance highlights, segmental performance, financial overview, and FY24 outlook. The document contains substantive financial data including revenue, gross profit, EBITDA, net loss, segmental results, and cost adjustments. It is not merely an announcement of a report but contains detailed financial and operational information typically found in an interim or quarterly report. The presence of half-year and full-year financial data, segmental analysis, and forward-looking statements aligns with the characteristics of an Interim / Quarterly Report (IR). It is not a full Annual Report (10-K) as it focuses on a shorter fiscal period and is presented as a conference presentation with financial results. Therefore, the most appropriate classification is Interim / Quarterly Report (IR). FY 2023
2023-09-10 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.